Jacob Asset Management of New York LLC Acquires 18,924 Shares of NeuBase Therapeutics, Inc. (NASDAQ:NBSE)

Jacob Asset Management of New York LLC boosted its position in NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Rating) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 426,424 shares of the company’s stock after purchasing an additional 18,924 shares during the period. Jacob Asset Management of New York LLC owned about 1.30% of NeuBase Therapeutics worth $1,198,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of NBSE. CM Management LLC raised its position in shares of NeuBase Therapeutics by 100.0% in the fourth quarter. CM Management LLC now owns 150,000 shares of the company’s stock worth $422,000 after buying an additional 75,000 shares in the last quarter. Heritage Wealth Advisors purchased a new stake in shares of NeuBase Therapeutics in the fourth quarter worth $28,000. Tocqueville Asset Management L.P. raised its position in shares of NeuBase Therapeutics by 156.9% in the third quarter. Tocqueville Asset Management L.P. now owns 74,000 shares of the company’s stock worth $267,000 after buying an additional 45,200 shares in the last quarter. GSA Capital Partners LLP raised its position in shares of NeuBase Therapeutics by 1.5% in the third quarter. GSA Capital Partners LLP now owns 351,178 shares of the company’s stock worth $1,268,000 after buying an additional 5,027 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its position in shares of NeuBase Therapeutics by 253.2% in the third quarter. Stonepine Capital Management LLC now owns 109,742 shares of the company’s stock worth $396,000 after buying an additional 78,672 shares in the last quarter. Institutional investors and hedge funds own 34.30% of the company’s stock.

Shares of NBSE traded down $0.11 during trading hours on Thursday, hitting $1.09. The company had a trading volume of 1,941 shares, compared to its average volume of 62,770. NeuBase Therapeutics, Inc. has a 52-week low of $1.09 and a 52-week high of $5.99. The stock’s 50 day moving average price is $1.62 and its 200 day moving average price is $2.27.

NeuBase Therapeutics (NASDAQ:NBSE – Get Rating) last posted its quarterly earnings data on Thursday, February 10th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. Equities research analysts forecast that NeuBase Therapeutics, Inc. will post -0.97 earnings per share for the current fiscal year.

Separately, Zacks Investment Research cut NeuBase Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 20th.

NeuBase Therapeutics Profile (Get Rating)

NeuBase Therapeutics, Inc, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.

See Also